49 results about "Atypical antipsychotic" patented technology

The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) an atypical antipsychotic or a pharmaceutically acceptable salt thereof, (ii) a 5-HT1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.

A method for identifying typical and atypical antipsychotics based on their ability to reduce neuronal / glial activity in specific brain regions upon dopaminergic neurotransmission is disclosed.

This invention encompasses compounds of the formula: where either R1 or R2 represents and the other represents hydrogen or straight or branched chain lower alkyl having 1-6 carbon atoms; and X is oxygen, methylene, or NH; Y is represents various inorganic and organic substituents; Z is hydrogen, amino or NHR6 where R6 is lowere alkyl having 1-6 carbon atoms; T is hydrogen, halogen, hydroxy, or lower alkoxy having 1-6 carbon atoms; and A is methylene, carbonyl or CHOH. These compounds are selective partial agonists or antagonists at brain monoamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Furthermore compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neurolepticagents. These compounds show unexpectedly atypical antipsychotic profiles (clozapine-like) in the animal models described in this patent.

The invention provides Asenapine tablets and a preparation method thereof. The tablets comprise the following components in percentages by weight: 10-50% of Asenapine, 30-80% of a filler, 3-20% of a disintegrating agent, 0.5-1% of lubricant, and 0.2-2.5% of a flavouring. The preparation method comprises the following steps: micronization is carried out for Asenapine and the filler, and the particle size is controlled at 0.5-20[mu]m; the fine powder obtained in the last step and partial disintegrating agent are prepared into a soft material with an ethanol water, and granulation is carried out with 24 mesh sieve; prepared fine granules are dried at 50-70 DEG C, and granulation is carried out with 20 mesh sieve; the residual disintegrating agent, the flavouring and the lubricant are added into dried particles in order, total mixing is carried out twice, one mixing is carried out before the lubricant is added, the other mixing is carried out after the lubricant is added, till intermediate detection is qualified, the tablets are compressed, and the product is prepared. Asenapine tablets are common tablets with coating or without coating, the product is a novel atypical antipsychotic drug; the drug has the advantages of fast drug absorption, high bioavailability, and usage convenience.

Methods and compositions for preventing or reducing weight gain and associated metabolic syndrome in patients receiving atypical antipsychotic drugs for treatment of mental illnesses are described. The invention comprises administering to a patient in need of treatment an effective amount of a dopamine agonist in conjunction with an effective amount of an atypical antipsyochotic drug. In one embodiment of the invention, the dopamine agonist is pramipexole. The dopamine agonist may be administered in a low dose, such as less than 1 mg per day of pramipexole. Examples of atypical antipsychotic drugs which may be administered in conjunction with the dopamine agonist include clozapine, olanzapine, quetiapine and risperadone.